title: Weight Maintenance with Litramine (IQP-G-002AS): A 24-Week Double-Blind, Randomized, Placebo-Controlled Study.
abstract: BACKGROUND
  Litramine (IQP-G-002AS) was shown to be effective and safe for weight loss in overweight and obese subjects. However, long-term effectiveness on maintenance of body weight loss has yet to be ascertained.
  
  
  OBJECTIVE
  To assess effect of Litramine on maintenance of body weight loss.
  
  
  METHODS
  A double-blind, randomised, placebo-controlled trial on overweight and obese patients was conducted over two sites in Germany for 24 weeks. Subjects with documented previous weight loss of 3% over the last 3-6 months were randomised to groups given either Litramine (3 g/day) or a matching placebo. Primary endpoints were difference of mean body weight (kg) between baseline and end of study and maintenance of initially lost body weight in verum group, where maintenance is defined as ≤1% weight gain.
  
  
  RESULTS
  Subjects who were taking Litramine lost significantly more body weight compared to the subjects taking placebo who gained weight instead (-0.62 ± 1.55 kg versus 1.62 ± 1.48 kg, p < 0.001). More importantly, 92% of subjects in Litramine group were able to maintain their body weight after initial weight loss, versus 25% in placebo group. No serious adverse events were reported throughout.
  
  
  CONCLUSIONS
  Litramine is effective and safe for long-term body weight maintenance. Trial Registration. This trial is registered with Clinicaltrials.gov identifier: NCT01505387.
authors.affiliation: Practice for General Medicine, Kurfürstendamm 157/158, 10709 Berlin, Germany.
authors.forename: Barbara
authors.initials: B
authors.lastname: Grube
authors.affiliation: Zaluvida Corporate Sdn Bhd, E-16 Plaza Mont Kiara, 2 Jalan Kiara, 50480 Kuala Lumpur, Malaysia.
authors.forename: Pee-Win
authors.initials: PW
authors.lastname: Chong
authors.affiliation: Analyze & Realize GmbH, Waldseeweg 6, 13467 Berlin, Germany.
authors.forename: Felix
authors.initials: F
authors.lastname: Alt
authors.affiliation: Analyze & Realize GmbH, Weißenseer Weg 111, 10369 Berlin, Germany.
authors.forename: Ralf
authors.initials: R
authors.lastname: Uebelhack
mesh_terms: D000328:Adult; D019440:Anti-Obesity Agents / Q000494:pharmacology / Q000627:therapeutic use*; D015992:Body Mass Index; D001835:Body Weight / Q000187:drug effects*; D003505:Cyclodextrins / Q000494:pharmacology / Q000627:therapeutic use; D004043:Dietary Fiber / Q000494:pharmacology / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D005858:Germany; D006801:Humans; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000188:drug therapy / Q000517:prevention & control*; D028321:Plant Preparations / Q000494:pharmacology / Q000627:therapeutic use*; D015431:Weight Loss / Q000187:drug effects*
chemical_list: D019440:Anti-Obesity Agents; D003505:Cyclodextrins; D004043:Dietary Fiber; D028321:Plant Preparations